These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Yan Y; Andriole GL; Humphrey PA; Kibel AS Cancer; 2002 Sep; 95(6):1239-46. PubMed ID: 12216091 [TBL] [Abstract][Full Text] [Related]
12. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939 [TBL] [Abstract][Full Text] [Related]
13. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. Yutkin V; Pode D; Pikarsky E; Mandelboim O J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285 [TBL] [Abstract][Full Text] [Related]
14. Advances in the management of superficial bladder cancer. O'Donnell MA Semin Oncol; 2007 Apr; 34(2):85-97. PubMed ID: 17382792 [TBL] [Abstract][Full Text] [Related]
15. The management of superficial transitional cell carcinoma of the bladder. Sengupta S; Blute ML Urology; 2006 Mar; 67(3 Suppl 1):48-54; discussion 54-5. PubMed ID: 16530076 [TBL] [Abstract][Full Text] [Related]
16. [Treatment and follow-up of superficial bladder cancer]. Raitanen M Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168 [No Abstract] [Full Text] [Related]